Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

BACKGROUND: Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and symptoms, including HRQoL, among patients with active PsA. This analysis evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B., Mease, Philip J., Schett, Georg, Kirkham, Bruce, Strand, Vibeke, Williams, Nicole, Fox, Todd, Pricop, Luminita, Jugl, Steffen M., Gandhi, Kunal K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992664/
https://www.ncbi.nlm.nih.gov/pubmed/29880010
http://dx.doi.org/10.1186/s13075-018-1610-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992664/
https://www.ncbi.nlm.nih.gov/pubmed/29880010
http://dx.doi.org/10.1186/s13075-018-1610-3

Ejemplares similares